(Q33430655)

English

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

Hagop Kantarjian

17

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Elias Jabbour

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Guillermo Garcia-Manero

1

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gianluca Gaidano

7

object named as

Gianluca Gaidano

2 references

Europe PubMed Central

PubMed publication ID

26 July 2017

ORCID Public Data File 2021

Uwe Platzbecker

10

object named as

Uwe Platzbecker

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David P. Steensma

11

object named as

David P Steensma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Everett Peter Greenberg

9

object named as

Peter Greenberg

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mikkael A Sekeres

5

object named as

Mikkael A Sekeres

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lewis B Silverman

21

object named as

Lewis R Silverman

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

object named as

Gail J Roboz

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

object named as

Bart L Scott

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

object named as

Aref Al-Kali

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

object named as

Lucy A Godley

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15

object named as

Ehab Atallah

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Maria R Baer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suman Kambhampati

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karl-Anton Kreuzer

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Collins

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francois E Wilhelm

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nozar Azarnia

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ONTIME study investigators

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

8 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

496-508

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypomethylating agents and other novel strategies in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of novel cell cycle inhibitors in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-related clonal hematopoiesis associated with adverse outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900009-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)00009-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_ftt4vipx3vdu5gusvqjftgrgq4

1 reference

https://api.fatcat.wiki/v0/release/ftt4vipx3vdu5gusvqjftgrgq4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33430655&oldid=2095825985"